65,437 trials
Immune Thrombocytopenia
Primary: Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL — 6; 3; 6; 3 participants
Gonorrhoea
Primary: Maximum Observed Concentration (Cmax) of Zoliflodacin — 20863 ng/mL
Chronic Obstructive Pulmonary Disease
Primary: Detection of Expiratory Flow Limitation — 2.6 cmH2O*s/L
Infection · Wound Healing Problem · Nonunion
Primary: The Number of Participants With Re-operations (All Subsequent Operative Procedures to Treat an Infection, a Wound Healing Problem, or a Nonunion). — 7; 6; 3; 10…
Mobility Limitation
Primary: 1 Repetition Maximum Muscle Strength 1-RM (N) Double Leg Press — 1223; 1256; 1483; 1465 N
Osteoarthritis
Primary: Length of Hospital Stay — 30; 26 hours
Stroke
Primary: Walking Speed — 0.13 meters per second — p=0.0042
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Advanced Solid Tumors · Lymphomas
Primary: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) — 30 mg
Proliferative Diabetic Retinopathy (PDR)
Primary: Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS) — -4.6; -0.9; -1.7 square millimeters — p=0.0344
Cervical Disc Degenerative Disorder
Primary: Change in NDI From Baseline — 52.1; 28.5; 24.0 score on a scale
Psoriasis
Primary: Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set) — 10; 2; 9; 1 Participants
Influenza Virus Vaccine
Primary: Levels of Cytokine Interferon Gamma (IFN-gamma) Responses to Inactivated Influenza Vaccine — 1.3; 1.4; 1.3; 6.9 pg/mL
Jaw, Edentulous, Partially
Primary: Radiographic Bone Level Change at the Mesial and Distal of the Implants Between Baseline and One Year Post Treatment — 0.73; 0.22 mm
Metastatic Esophageal Cancer · Gastroesophageal Cancer · Gastric Cancer
Primary: Response — 3; 0; 2; 0 Participants